In most recent advancements, RNA editing uses the CRISPR-Cas13 system, a newer technique that was created specifically to help develop therapies that work with RNA. DNA editing is permanent, which ...

Mammalian RNAs can be edited by the conversion of adenosine to inosine, which is read as guanosine, but technological constraints have limited our view of the overall contribution of RNA editing ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible.

It’s the same when trying to fix a genetic problem. Rather than fix it at source (DNA editing), you can upload a patch (RNA editing), which is less complex, more efficient and carries less risk.” ...

The researchers for the first time used an RNA editing tool—known as CRISPR Cas13—to suppress the production of Vascular ...

Furthermore, ProQR has revealed advancements in its RNA-editing programs, including candidates for Rett Syndrome and NASH, indicating a robust pipeline with the potential for multiple trials in ...

ProQR Therapeutics announced significant advancements in their Axiomer RNA-editing platform during their 2024 Investor and Analyst Event. The company highlighted the platform’s potential to ...

The company's approach to RNA editing has garnered attention from both the scientific community and potential pharmaceutical partners. WaVe's HD program has faced a significant setback with Takeda ...

ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today ...

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ...